Mycovia Pharmaceuticals Completes Enrollment in its Third Phase 3 Clinical Trial for VT-1161 (ultraVIOLET) in Patients with Recurrent Vulvovaginal Candidiasis

ultraVIOLET trial evaluating efficacy of VT-1161 compared to fluconazole with topline data expected in 2H2020

Durham, N.C. – December 18, 2019 – Mycovia Pharmaceuticals, Inc. (“Mycovia”) today announced it has completed enrollment for its ongoing Phase 3 ultraVIOLET clinical trial for VT1161. Mycovia is developing VT-1161, an oral antifungal product candidate, for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that affects nearly 138 million women worldwide each year and for which there is currently no approved treatment in the U.S.